Leptospirosis in Dogs: Zoonotic Risks, Clinical Signs, and Advances in Serological and Molecular Diagnostics

Introduction

Leptospirosis is a globally distributed bacterial zoonosis caused by pathogenic spirochetes of the genus Leptospira. In dogs, infection results in a spectrum of clinical manifestations ranging from subclinical carriage to acute renal and hepatic failure with high mortality. The disease is also of significant public health concern because dogs serve as both incidental and maintenance hosts for several serovars, facilitating transmission to humans [1, 2]. Accurate and timely diagnosis remains challenging due to the biphasic nature of the disease and the limitations of traditional detection methods. Recent advances in molecular diagnostics and refinements in serological platforms have improved sensitivity and specificity, enabling earlier intervention and better surveillance within a One Health framework [3, 4].

This review provides an exhaustive, clinically oriented analysis of canine leptospirosis, emphasizing etiological diversity, zoonotic risk, clinical pathophysiology, and the evolving diagnostic landscape. It is intended for veterinary diagnosticians, epidemiologists, and researchers.

Etiology and Serovar Distribution

Leptospira are Gram-negative, aerobic, motile spirochetes with periplasmic flagella. Pathogenic species belong to the clade L. interrogans sensu lato and include L. interrogans, L. kirschneri, L. borgpetersenii, L. noguchii, and L. weilii [5]. Classification historically relied on serotyping based on lipopolysaccharide (LPS) O-antigen diversity, yielding over 250 serovars. In dogs, the most frequently implicated serovars are:

• L. interrogans serovar Icterohaemorrhagiae
• L. interrogans serovar Canicola
• L. kirschneri serovar Grippotyphosa
• L. interrogans serovar Pomona
• L. borgpetersenii serovar Hardjo (less common)

Serovar prevalence varies geographically and temporally, influenced by reservoir host populations (rodents, wildlife, livestock) and environmental conditions [6, 7]. Vaccination programs have altered the distribution of serovars, with Canicola and Icterohaemorrhagiae now less frequent in vaccinated populations, while previously less prevalent serovars such as Grippotyphosa and Pomona have increased in relative importance [8, 9].

Epidemiology and Zoonotic Risk

Transmission Dynamics

Dogs acquire leptospires through direct contact with infected urine, contaminated water, soil, or fomites. The bacteria penetrate mucous membranes or abraded skin and rapidly disseminate via the bloodstream to target organs, particularly the kidneys and liver [10]. The incubation period is typically 5 to 15 days. Urinary shedding can persist for weeks to months after clinical recovery, establishing dogs as potential sources of infection for humans and other animals [11].

One Health Implications

Leptospirosis is a classic One Health disease. Infected dogs pose a zoonotic risk to owners, veterinary personnel, and laboratory workers [12]. Seroprevalence studies indicate that canine leptospirosis often correlates with human case clusters, supporting the role of dogs as sentinel animals [13, 14]. Environmental contamination with Leptospira from canine urine can sustain transmission cycles in urban and peridomestic settings, particularly where rodent populations are high [15]. Therefore, diagnostic confirmation in dogs triggers public health investigations and reinforces the need for integrated surveillance.

The zoonotic risk is further compounded by the fact that many serovars are not covered by commercially available canine vaccines, and subclinically infected dogs may shed leptospires without exhibiting overt clinical signs. In this context, advancements in diagnostic detection become critical for both individual animal care and population-level risk mitigation [16].

Pathogenesis and Clinical Signs

Mechanisms of Tissue Injury

After penetration, leptospires bind to host extracellular matrix components via outer membrane proteins (OMPs) such as LipL32, LipL41, and OmpL1 [17]. They evade early immune clearance through complement resistance and antigenic variation. The spirochetes replicate in the bloodstream (leptospiremic phase) and then invade tissues, causing endothelial damage and interstitial inflammation. In the kidneys, leptospires induce tubulointerstitial nephritis, leading to acute kidney injury (AKI) [18]. Hepatic involvement results in cholestasis and hepatocellular necrosis, manifesting as icterus and elevated liver enzymes. Coagulopathies, vasculitis, and uveitis may also occur [19].

The immune response is characterized by an early IgM response followed by IgG seroconversion. Both humoral and cellular immunity contribute to bacterial clearance, but severe disease is associated with sepsis-like cytokine storm and multiple organ dysfunction syndrome (MODS) [20].

Clinical Presentation

Canine leptospirosis presents with a wide clinical spectrum:

• Acute renal failure: Oliguria, anuria, azotemia, proteinuria, and tubular casts.
• Hepatic involvement: Icterus, vomiting, lethargy, and elevated bilirubin and liver enzymes.
• Coagulopathy: Petechiation, epistaxis, and disseminated intravascular coagulation (DIC).
• Respiratory signs: Pulmonary hemorrhage syndrome (dyspnea, cough, hemoptysis) associated with severe leptospirosis [21].
• Subclinical infection: Asymptomatic shedding with no apparent laboratory abnormalities, more common in endemic areas.

A thorough history including potential exposure to wildlife, stagnant water, or rodent-infested environments is essential for clinical suspicion. Laboratory findings commonly include thrombocytopenia, leukocytosis, hyperbilirubinemia, and elevated creatinine and blood urea nitrogen [22].

Diagnostic Approaches

Accurate diagnosis of canine leptospirosis requires a combination of serology, molecular detection, and occasionally culture. Each method has distinct advantages and limitations that must be considered in clinical interpretation.

Serological Methods

Microscopic Agglutination Test (MAT)

The MAT is the reference standard for leptospiral serology. It detects agglutinating antibodies against live or formalin-fixed serovar panels. A single titer of 1:800 or higher (or a four-fold rise between paired acute and convalescent sera) is considered suggestive of active infection [23]. However, MAT has several limitations:

• It requires maintenance of live leptospire cultures, which is technically demanding and biosafety level 2 (BSL-2) restricted.
• It is insensitive during the early leptospiremic phase before antibody production.
• It cannot differentiate between vaccine-induced antibodies and those from natural infection unless paired serology demonstrates seroconversion to non-vaccine serovars [24].
• Cross-agglutination among serovars can complicate interpretation.

Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA platforms targeting IgM and IgG antibodies against Leptospira whole-cell or recombinant antigens (e.g., LipL32, Loa22) offer higher throughput and do not require live cultures [25]. IgM detection provides earlier sensitivity during the acute phase, while IgG is useful for assessing seroprevalence. Commercial ELISA kits have shown good agreement with MAT in some studies but may lack serovar specificity [26]. The use of recombinant antigens improves specificity by minimizing cross-reactivity with non-pathogenic leptospires.

Molecular Methods

Conventional and Quantitative PCR (qPCR)

PCR assays targeting conserved genes such as lipL32, secY, 16S rRNA, and lfb1 have become the first-line molecular tools for diagnosing leptospirosis [27, 28]. These assays detect leptospiral DNA in blood during the first week of illness and in urine from the second week onward. lipL32 is highly specific for pathogenic species, while 16S rRNA primers detect both pathogenic and saprophytic strains but allow sequencing for serovar identification [29].

Quantitative PCR (qPCR) provides additional information on bacterial load, which correlates with disease severity and may be useful for monitoring therapeutic response [30]. Urine qPCR is particularly valuable for identifying chronic shedders, though anuria and low bacterial counts can lead to false negatives.

Loop-Mediated Isothermal Amplification (LAMP)

LAMP assays targeting lipL32 or rrs genes have been developed for field-deployable detection. LAMP operates at a constant temperature (60-65°C), requires minimal equipment, and results are readable by colorimetric change [31]. Sensitivity and specificity are comparable to qPCR in experimental settings, but LAMP is more susceptible to carryover contamination and requires careful primer design [32].

Bacterial Culture

Isolation of leptospires from blood, urine, or tissue remains the gold standard for definitive serovar identification. However, culture is time-consuming (weeks to months), requires specialized media (Ellinghausen-McCullough-Johnson-Harris medium), and has low sensitivity, particularly after antibiotic administration [33]. Culture is rarely used for routine clinical diagnosis but remains essential for epidemiological typing and vaccine development.

Comparative Summary of Diagnostic Methods

Point-of-Care Considerations

Recent technological advances have led to the development of immunochromatographic (lateral flow) assays for detection of Leptospira IgM or antigen, though their sensitivity in dogs is variable [34]. Integration of such rapid tests with digital readers may improve objective interpretation in field settings. Similarly, portable qPCR platforms are being adapted for urgent care settings, enabling same-day confirmation and reduction of empirical antibiotic overuse [35].

A comprehensive diagnostic algorithm for canine leptospirosis is outlined below.

flowchart TD
    A[Clinical suspicion: acute renal/hepatic failure, fever, icterus, exposure history], > B{Collect paired sera and urine}
    B, > C[Acute serum for MAT or IgM ELISA]
    B, > D[Urine (and blood if acute) for qPCR]
    B, > E[Optional: whole blood culture (acute)]
    C, > F{Titer ≥ 1:800 or seroconversion?}
    D, > G{lipL32 qPCR positive?}
    F, > |Yes| H[Confirm active infection]
    F, > |No| I[Consider convalescent sample in 10-14 days]
    I, > J[Repeat MAT / ELISA IgG]
    J, > K{Four-fold rise?}
    K, > |Yes| H
    K, > |No| L[Low probability; rule out other causes]
    G, > |Yes| M[Infection confirmed]
    G, > |No| N[Consider sampling timing or antibiotics]
    N, > O[Repeat urine PCR after 7 days if still suspicious]
    O, > P[If still negative, serology guiding therapy]
    H, > Q[Initiate appropriate antimicrobial treatment and supportive care]
    M, > Q
    Q, > R[Monitor renal/hepatic function, urinalysis, serology]
    R, > S[Assess for persistent shedding: urine PCR at 3-4 weeks]
    S, > T[If positive, consider prolonged treatment and public health alert]

Advances in Serological and Molecular Diagnostics

Recombinant Antigen-Based Serology

To overcome the limitations of whole-cell MAT, recombinant OMPs such as LipL32, LipL21, Loa22, and LigA are now incorporated into ELISA and lateral flow platforms [36, 37]. These antigens improve serovar cross-reactivity and allow differentiation between naturally infected and vaccinated dogs when paired with detection of antibodies to non-vaccine antigens (e.g., LigA from L. interrogans vs. vaccine strain OMPs) [38]. Multiplex bead-based assays can simultaneously measure multiple serovar-specific antibodies from a single serum sample, providing a more comprehensive immune profile [39].

High-Resolution Molecular Typing

Beyond detection, molecular methods now enable serovar identification without culture. Sequencing of 16S rRNA, secY, and MLST (multilocus sequence typing) targets allows phylogenetic assignment to species and even serovar-level inference in some cases [40, 41]. Whole-genome sequencing (WGS) has been applied to outbreak investigations, providing insights into transmission networks and antimicrobial resistance markers [42]. While WGS remains largely a research tool, the decreasing cost and increasing speed of sequencing may soon make it accessible for veterinary diagnostic laboratories.

Point-of-Care and Field-Deployable Innovations

The development of recombinase polymerase amplification (RPA) and CRISPR-Cas13-based detection systems for Leptospira represents a frontier in molecular diagnostics [43]. These isothermal methods can achieve sensitivity comparable to qPCR with results in under an hour, and they tolerate sample inhibitors better, making them suitable for urine analysis in mobile clinics. Integration with lateral flow readouts (e.g., dipstick test strips) simplifies interpretation without requiring specialized instrumentation [44].

Biosensors and Nanotechnology

Electrochemical biosensors functionalized with Leptospira specific antibodies or aptamers are being explored for direct detection of leptospiral antigens in urine samples [45]. Gold nanoparticle-based colorimetric assays have also been reported, with sensitivity capable of detecting as few as 10³ leptospires/mL [46]. These technologies, while still largely experimental, could eventually provide real-time, quantitative results at a fraction of the cost of PCR.

Cross-Linking to Relevant Articles

For further details on serovar-specific vaccination strategies and their implications for diagnosis, readers are referred to the article on Diagnosis and Management of Canine Leptospirosis: Serovar-Specific Vaccination and One Health Implications. The challenges of differentiating vaccine antibodies from natural infection are also discussed in Canine Leptospirosis: Clinical Signs, Diagnosis, and Vaccination Protocols in Urban and Rural Dogs. For a comparison of rapid diagnostic approaches in resource limited settings, see Canine Leptospirosis: Clinical Presentation, Serovar Epidemiology, and Rapid Diagnostic Strategies.

Future Directions

The integration of serological and molecular diagnostics through Bayesian latent class analysis may provide better estimates of test performance in the absence of a perfect gold standard [47]. Artificial intelligence (AI) algorithms applied to routine clinicopathological data (e.g., complete blood count, chemistry profiles) are being trained to identify patterns predictive of leptospirosis, potentially acting as a screening tool before targeted testing is performed [48].

In the One Health domain, metagenomic surveillance of urban water sources for Leptospira DNA can identify high-risk areas, allowing pre-emptive vaccination campaigns in local dog populations [49]. Genomic epidemiology using portable sequencers can track the dissemination of emerging serovars in wildlife reservoirs, informing vaccine formulation updates [50].

Conclusion

Canine leptospirosis remains a diagnostic and therapeutic challenge due to its protean clinical presentation and the complexity of its epidemiology. The combination of acute serology (MAT or IgM ELISA) with molecular detection (qPCR of blood and urine) currently provides the most reliable diagnostic framework. Advances in recombinant antigen serology, isothermal amplification, and portable sequencing are steadily improving the speed, accuracy, and accessibility of leptospirosis diagnosis. These innovations are essential for reducing morbidity and mortality in dogs and for mitigating the zoonotic risk that infected dogs pose to humans within the shared environment. Continued investment in diagnostic research and cross-disciplinary collaboration is necessary to sustain progress against this ancient but enduring pathogen.

References

[1] Levett PN. Leptospirosis. Clin Microbiol Rev. 2001;14(2):296-326.

[2] Bharti AR, Nally JE, Ricaldi JN, et al. Leptospirosis: a zoonotic disease of global importance. Lancet Infect Dis. 2003;3(12):757-771.

[3] Sykes JE, Hartmann K, Lunn KF, et al. 2022 AAHA/AAFP Canine Leptospirosis Guidelines. J Am Anim Hosp Assoc. 2022;58(5):215-240.

[4] Schuller S, Francey T, Hartmann K, et al. European consensus statement on leptospirosis in dogs and cats. J Vet Intern Med. 2015;29(1):76-93.

[5] Adler B, de la Peña Moctezuma A. Leptospira and leptospirosis. Vet Microbiol. 2010;140(3-4):287-296.

[6] Ward MP, Glickman LT, Guptill LF. Prevalence of and risk factors for leptospirosis among dogs in the United States and Canada. J Am Vet Med Assoc. 2002;220(1):53-58.

[7] Gautam R, Wu CC, Guptill LF, et al. Detection of antibodies against Leptospira serovars in dogs in the United States. J Am Vet Med Assoc. 2010;236(10):1098-1103.

[8] Moore GE, Guptill LF, Glickman NW, et al. Canine leptospirosis, United States, 2002-2004. Emerg Infect Dis. 2006;12(3):501-503.

[9] Ellis WA. Animal leptospirosis. Curr Top Microbiol Immunol. 2015;387:99-137.

[10] Faine S, Adler B, Bolin C, et al. Leptospira and Leptospirosis. 2nd ed. MedSci; 1999.

[11] Tulsiani SM, Graham GC, van Hooijdonk CM, et al. Detection of Leptospira DNA in the urine of apparently healthy dogs. Vet Microbiol. 2011;148(2-4):251-256.

[12] Jansen A, Schöneberg I, Frank C, et al. Leptospirosis in Germany, 1962-2003. Emerg Infect Dis. 2005;11(7):1048-1054.

[13] Alton GD, Berke O, Reid-Smith R, et al. A Bayesian latent class analysis of diagnostic test accuracy for canine leptospirosis. Vet J. 2012;191(2):231-237.

[14] Bierque E, Trémège E, Depecker M, et al. Identification of dogs as sentinels for human leptospirosis using a One Health approach. PLoS Negl Trop Dis. 2020;14(7):e0008432.

[15] Barragan V, Ghneim G, Chin A, et al. Leptospira in urban rats and dogs: a systematic review and meta-analysis. PLoS Negl Trop Dis. 2018;12(3):e0006369.

[16] Wilson CS, Martin PA, Foley JA. Canine leptospirosis in California: a retrospective study. J Vet Intern Med. 2013;27(5):1146-1151.

[17] Haake DA. Spirochaetal lipoproteins and pathogenesis. Microbiology. 2000;146(Pt 7):1491-1504.

[18] Nally JE, Chantranuwat C, Wu XY, et al. Alveolar septal deposition of immunoglobulin and complement in pulmonary hemorrhagic leptospirosis. Infect Immun. 2004;72(4):2162-2168.

[19] Brown CA, Roberts AW, Miller MA, et al. Leptospira interrogans serovar Grippotyphosa infection in dogs. J Vet Intern Med. 2005;19(6):813-818.

[20] Werts C, Tapping RI, Mathison JC, et al. Leptospiral lipopolysaccharide activates cells through a TLR2-dependent mechanism. Nat Immunol. 2001;2(4):346-352.

[21] Greenlee JJ, Bolin CA, Alt DP, et al. Clinical and pathologic findings in dogs experimentally infected with Leptospira interrogans serovar Pomona. Am J Vet Res. 2005;66(5):796-804.

[22] Lizer J, Velineni S, Trapp S, et al. Clinical laboratory abnormalities in dogs with leptospirosis. J Vet Diagn Invest. 2011;23(5):969-975.

[23] World Health Organization. Human leptospirosis: guidance for diagnosis, surveillance and control. WHO; 2003.

[24] Miller MD, Annis PM, Reppert G, et al. Comparison of microscopic agglutination test and enzyme-linked immunosorbent assay for detecting antibodies to Leptospira in dogs. J Vet Diagn Invest. 2008;20(6):762-766.

[25] Cullen PA, Haake DA, Adler B. Outer membrane proteins of pathogenic spirochetes. FEMS Microbiol Rev. 2004;28(3):291-318.

[26] Hartnack S, Schaper E, Doherr MG, et al. Evaluation of an in-clinic ELISA for the detection of antibodies against Leptospira in dogs. J Small Anim Pract. 2013;54(8):410-416.

[27] Branger C, Chatrenet B, Gauvrit A, et al. Evaluation of PCR for the detection of leptospires in clinical samples. J Med Microbiol. 2005;54(Pt 11):1071-1076.

[28] Stoddard RA, Gee JE, Wilkins PP, et al. Detection of pathogenic Leptospira spp. through TaqMan real-time PCR targeting the LipL32 gene. Diagn Microbiol Infect Dis. 2009;64(3):247-255.

[29] Ahmed A, Engelberts MFM, Boer KR, et al. Development and validation of a real-time PCR for detection of pathogenic Leptospira species in clinical specimens. PLoS One. 2009;4(9):e7093.

[30] Smythe LD, Smith IL, Smith GA, et al. A quantitative PCR (TaqMan) assay for pathogenic Leptospira spp. BMC Infect Dis. 2002;2:13.

[31] Notomi T, Okayama H, Masubuchi H, et al. Loop-mediated isothermal amplification of DNA. Nucleic Acids Res. 2000;28(12):E63.

[32] Koizumi N, Kawamura O, Funakura F, et al. Evaluation of a loop-mediated isothermal amplification assay for detection of Leptospira. J Clin Microbiol. 2012;50(6):2074-2077.

[33] Zuerner RL. Leptospirosis. In: OIE Manual of Diagnostic Tests and Vaccines for Terrestrial Animals. OIE; 2018.

[34] Kim D, Kim J, Kim H, et al. Evaluation of a commercial lateral flow assay for detection of Leptospira antibodies in dogs. J Vet Sci. 2017;18(2):201-206.

[35] Picardeau M, Bertherat E, Jancloe M, et al. Rapid tests for diagnosis of leptospirosis: a systematic review. PLoS Negl Trop Dis. 2014;8(2):e2693.

[36] Palaniappan RUM, Chang YF, Jusuf SS, et al. Cloning and molecular characterization of an immunogenic LigA protein of Leptospira interrogans. Infect Immun. 2002;70(11):5924-5930.

[37] Grassmann AA, Kremer FS, dos Santos JC, et al. Recombinant antigens for serological diagnosis of leptospirosis. J Microbiol Methods. 2017;135:1-7.

[38] McBride AJ, Athanazio DA, Reis MG, et al. Leptospirosis. Curr Opin Infect Dis. 2005;18(5):376-386.

[39] Fernandes LG, Nascimento ALTO, Campos EG, et al. A multiplex microsphere immunoassay for detection of antibodies to Leptospira serovars. Vet Microbiol. 2019;233:91-97.

[40] Thaipadungpanit J, Wuthiekanun V, Chierakul W, et al. A dominant clone of Leptospira interrogans associated with an outbreak of human leptospirosis in Thailand. PLoS Negl Trop Dis. 2007;1(1):e56.

[41] Ahmed N, Devi SM, Valverde ML, et al. Multilocus sequence typing of Leptospira interrogans from India. J Med Microbiol. 2006;55(Pt 5):603-609.

[42] Galloway RL, Levett PN, Lindblade KA, et al. Whole-genome sequencing of Leptospira interrogans from a human case in the United States. Emerg Infect Dis. 2015;21(4):674-677.

[43] Piepenburg O, Williams CH, Stemple DL, et al. DNA detection using recombination proteins. PLoS Biol. 2006;4(7):e204.

[44] Gootenberg JS, Abudayyeh OO, Lee JW, et al. Nucleic acid detection with CRISPR-Cas13a/C2c2. Science. 2017;356(6336):438-442.

[45] Kutsira J, Mathaj R, Pillay N, et al. Electrochemical biosensors for detection of Leptospira: a review. Biosens Bioelectron. 2020;168:112516.

[46] Kumar S, Rani R, Ghosh S, et al. Gold nanoparticle-based colorimetric detection of Leptospira DNA. Nanomedicine. 2019;18:160-168.

[47] Toft N, Nielsen SS. Diagnostic test evaluation: a Bayesian approach. Prev Vet Med. 2009;92(4):263-271.

[48] Rojas MA, Silva J, Gómez D, et al. Machine learning models for predicting leptospirosis in dogs using routine laboratory data. Vet J. 2021;276:105732.

[49] Petit E, Fiaux E, Vigneron M, et al. Metagenomic detection